南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停

Lin28A通过抑制肝星状细胞中HMGA2/HIF-1α依赖性铁死亡驱动肝纤维化

Lin28A Drives hepatic fibrosis by suppressing HMGA2/HIF-1α-Dependent ferroptosis in hepatic stellate cells

Ankang Wang, Hongfa Sun, Haixia Zhao, Ye Xie, Mengchao Yan, Yue Zhang, Xiaojing Song, Fanghui Ding, Changpeng Chai, Haixu Ni, Jia Yao, Xun Li

Journal:BIOCHEMICAL PHARMACOLOGY

IF:6.5

DOI:10.1016/j.bcp.2026.117900

PMID:41850661

Published:2026-03-16

research field:分子生物学细胞生物学肝脏病学RNA生物学纤维化研究

Abstract

Effective therapies for liver fibrosis are lacking. The RNA-binding protein Lin28A is upregulated in human cirrhotic and mouse fibrotic livers, where it localizes to activated hepatic stellate cells (HSCs). HSCs-specific overexpression of Lin28A worsened carbon tetrachloride (CCl 4 )-induced fibrosis in mice. In LX-2 and primary mouse HSCs, Lin28A knockdown suppressed activation and induced hallmarks of ferroptosis, including mitochondrial damage, lipid peroxidation, and glutathione depletion. Mechanistically, Lin28A repressed the maturation of let-7 microRNAs, leading to increased expression of its target, high-mobility group AT-hook 2 (HMGA2). HMGA2, alongside hypoxia-inducible factor-1α (HIF-1α), contributed to the downregulation of the ferroptosis defense proteins SLC7A11 and GPX4. Notably, the anti-fibrotic effects of the Lin28A inhibitor C1632 were dependent on ferroptosis induction, as co-treatment with ferrostatin-1 reversed its impact on HSCS activation and death. In vivo, C1632 treatment alleviated CCl 4 -induced liver fibrosis. These results identify Lin28A as a regulator of HSCS ferroptosis and a potential target for anti-fibrotic therapy.

本文使用的Yeasen产品

购物车
客服
转染试用